Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 7Not yet recruiting 3Unknown 2Terminated 1Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Endometrial Cancer 2Thrombosis 1Thrombophilia 1Solid Tumors 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Metastatic Solid Tumors 1Melanoma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 8Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 4Cisplatin 4Blood Specimen Collection 4cemiplimab 3Interviews as Topic 3Injections 3Exercise 3Early Intervention, Educational 3pembrolizumab 2durvalumab 2atezolizumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiosurgery 2Observation 2Nivolumab 2Methods 2Magnetic Resonance Imaging 2Immunotherapy 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × Injections × Clear all
NCT06809946 2026-03-30

DEFLECT I

University Medical Center Groningen

Phase 2 Not yet recruiting
20 enrolled
Thoracic

Lung Neoplasms

NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

NCT06948539 2025-04-29

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡